Search

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

New analysis supports long-term treatment with Ofev® in SSc-ILD patients

Focus on Alliance Management

FDA Grants OFEV® (nintedanib) BTD for Chronic Fibrosing ILDs | Boehringer Ingelheim US

FDA grants Breakthrough Therapy Designation to OFEV for chronic fibrosing ILDs with a progressive phenotype. View ISI, PI and Med Guide.

OFEV® (nintedanib) Data in Patients with ILDs | Boehringer Ingelheim US

Studies from American Thoracic Society Congress show the proportion of patients with 10% or greater declines in lung function were lower in the OFEV group.

Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease

Boehringer Ingelheim announces InPedILD PhaseIII trial results

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

The findings demonstrate the benefit of clinic-level educational interventions

Tackling Health Disparities and Inequities for Women With Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care

Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care

Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US

BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Real-world study shows sequencing of Gilotrif

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US

The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers